Prognostic significance of germline ARID5B and LEPR polymorphisms in intrahepatic and perihilar cholangiocarcinoma after curative resection

doi:10.4251/wjgo.120469

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(4)

(0)

(54)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 120469
Published online Jul 15, 2026. doi: 10.4251/wjgo.120469

Table 1 Patient characteristics, n (%)/median and interquartile range

Variables	iCCA (n = 112)	pCCA (n = 117)
Demographics
Gender, M/F (%)	49 (43.8)/63 (56.3)	78 (66.7)/39 (33.3)
Age (years)	65 (58-75)	69 (58-74)
ASA
I	3 (2.7)	6 (5.1)
II	45 (40.2)	47 (40.2)
III	59 (52.7)	58 (49.6)
IV	5 (4.5)	6 (5.1)
V	0	0
Bismuth type
I		7 (6.0)
II		13 (11.1)
IIIa		29 (24.8)
IIIb		33 (28.2)
IV		35 (29.9)
Cholangitis	4 (3.6)	30 (25.6)
Portal vein embolization	7 (6.3)	41 (35.0)
Preoperative chemotherapy	9 (8.0)	5 (4.3)
Clinical chemistry
AST (U/L)	34 (26-47)	47 (34-95)
ALT (U/L)	29 (20-49)	69 (36-144)
Albumin (g/dL)	4.4 (4.0-4.6)	3.9 (3.5-4.2)
AP (U/L)	118 (84-215)	254 (159-423)
CA19-9 (U/mL)	39.5 (13.9-236.3)	85.8 (31.2-287.7)
CRP (mg/L)	7.5 (2.8-19.4)	11.8 (5.4-34.7)
GGT (U/L)	113 (65-275)	472 (216-756)
Hemoglobin (g/dL)	13.1 (12.2-14.3)	12.4 (11.2-13.3)
INR	1.0 (0.9-1.1)	1.0 (0.9-1.1)
Platelet count (nL)	252 (202-306)	293 (229-388)
Prothrombin time (%)	100 (90-108)	96 (81-105)
Total bilirubin (mg/dL)	0.5 (0.3-0.7)	1.1 (0.5-2.8)
Operative data
Intraoperative PRBC	31 (72.3)	54 (46.2)
Intraoperative FFP	38 (33.9)	68 (58.1)
Operative time (minutes)	295 (230-359)	420 (356-485)
Operative procedure
Hemihepatectomy	44 (39.2)	29 (24.8)
Extended hemihepatectomy	17 (15.1)	54 (46.2)
Trisectionectomy	12 (10.8)	24 (20.6)
Hepatoduodenoectomy	0 (0)	5 (4.3)
ALPPS	10 (8.9)	1 (0.9)
Others	29 (25.8)	4 (3.4)
Time to surgery (days¹)	45 (29-83)	38 (24-56)
Pathological examination
LVI	20 (17.9)	26 (22.2)
MVI	5 (4.5)	2 (1.7)
R0 resection	97 (86.6)	97 (82.9)
pT category
1	46 (41.1)	10 (8.6)
2	46 (41.1)	72 (61.5)
3	12 (10.7)	26 (22.2)
4	8 (7.1)	9 (7.7)
pN category
N0	69 (61.6)	67 (57.3)
N1	34 (30.4)	50 (42.7)
Tumor grading
G1	0	7 (6.0)
G2	73 (65.2)	83 (70.9)
G3	26 (23.2)	22 (18.8)
G4	3 (2.7)	1 (0.9)
Postoperative data
Intensive care (days)	1 (1-1)	1 (1-2)
Hospitalization (days)	12 (8-22)	17 (12-36)
Postoperative complications
No complications	43 (38.4)	19 (16.2)
Clavien-Dindo I	4 (3.6)	8 (6.8)
Clavien-Dindo II	24 (21.4)	33 (28.2)
Clavien-Dindo IIIa	25 (22.3)	25 (28.2)
Clavien-Dindo IIIb	10 (8.9)	19 (16.2)
Clavien-Dindo IVa	5 (4.5)	8 (6.8)
Clavien-Dindo IVb	1 (0.9)	5 (4.3)
Clavien-Dindo V	0	0
Oncologic data
Adjuvant chemotherapy	42 (37.5)	31 (26.5)
Recurrence	77 (68.8)	64 (54.7)
Median RFS, months (95%CI)	12 (7-17)	37 (23-51)
Median CSS, months (95%CI)	28 (21-35)	49 (24-74)
Median OS, months (95%CI)	25 (18-32)	33 (20-46)

¹Time to surgery refers to the time frame from diagnosis to surgery.

iCCA: Intrahepatic cholangiocarcinoma; pCCA: Perihilar cholangiocarcinoma; M: Male; F: Female; AP: Alkaline Phosphatase; ASA: American Society of Anesthesiology; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CA19-9: Carbohydrate antigen 19-9; CRP: C-reactive protein; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; PRBC: Packed red blood cells; FFP: Fresh frozen plasma; ALPPS: Associating liver partition with portal vein ligation for staged hepatectomy; LVI: Lymph vascular invasion; MVI: Microvascular invasion; CSS: Cancer-specific survival; OS: Overall Survival; RFS: Recurrence free survival.

Full Size Table

Table 2 Single nucleotide polymorphism frequencies and associations with recurrence-free survival, cancer-specific survival and overall survival in intrahepatic cholangiocarcinoma

SNP	n (%)	Recurrence-free survival				Cancer-specific survival				Overall survival
SNP	n (%)	Median (95%CI)	P value¹	HR (95%CI)	P value²	Median (95%CI)	P value¹	HR (95%CI)	P value²	Median (95%CI)	P value¹	HR (95%CI)	P value²
Recessive model
rs10740055			0.013				0.029				0.018
CC/CA	85 (75.9)	13 (8.7-17.1)		1		30 (18.3-41.7)		1		28 (21.0-35.0)		1
AA	26 (23.2)	8 (3.9-12.1)		1.866 (1.116-3.121)	0.017	16 (8.3-26.7)		1.776 (1.046-3.015)	0.033	12 (3.0-21.0)		1.791 (1.093-2.932)	0.021
rs11168249			0.125				0.662				0.332
TT/TC	94 (84.0)	13 (8.3-17.7)		1		28 (15.4-40.6)		1		25 (17.5-32.5)		1
CC	18 (16.1)	7 (4.6-9.4)		1.602 (0.861-2.982)	0.137	31 (17.5-44.5)		1.154 (0.603-2.208)	0.665	24 (9.4-38.6)		1.328 (0.742-2.378)	0.339
rs1137101			0.007				0.107				0.221
AA/AG	83 (74.1)	16 (10.3-21.7)		1		36 (21.7-50.3)		1		29 (15.9-42.1)		1
GG	29 (25.9)	7 (6.2-7.8)		1.910 (1.170-3.116)	0.010	20 (12.2-27.8)		1.506 (0.907-2.500)	0.113	20 (13.0-27.0)		1.342 (0.833-2.164)	0.227
rs2736100			0.879				0.782				0.610
CC/CA	75 (67.0)	13 (7.0-19.0)		1		30 (19.2-40.8)		1		28 (17.3-38.7)		1
AA	29 (25.9)	11 (5.6-16.4)		1.043 (0.610-1.781)	0.878	29 (10.0-47.9)		0.922 (0.517-1.646)	0.784	20 (9.4-30.5)		1.139 (0.687-1.889)	0.613
rs3748816			0.513				0.581				0.390
AA/AG	93 (83.0)	12 (6.1-17.9)		1		28 (14.7-41.3)		1		25 (16.5-33.5)		1
GG	18 (16.1)	11 (4.8-17.2)		0.823 (0.453-1.496)	0.523	27 (20.1-33.9)		0.841 (0.451-1.568)	0.585	27 (20.1-33.9)		0.773 (0.426-1.402)	0.397
rs7528484			0.188				0.078				0.193
CC/CT	86 (76.8)	10 (5.5-14.5)		1		29 (19.7-38.3)		1		25 (19.3-30.7)		1
TT	26 (23.2)	15 (10.4-19.6)		0.691 (0.392-1.217)	0.201	21 (0-48.2)		0.601 (0.321-1.126)	0.112	32 (0-77.8)		0.699 (0.404-1.209)	0.200
Co-dominant model
rs10740055			0.034				0.093				0.060
CC	27 (24.1)	10 (5.1-14.9)		1		30 (6.5-53.5)		1		29 (11.9-46.1)		1
CA	58 (51.8)	16 (12.3-19.7)		1.275 (0.711-2.288)	0.415	31 (18.8-43.2)		1.007 (0.557-1.821)	0.981	28 (19.8-36.2)		0.987 (0.572-1.702)	0.962
AA	26 (23.2)	8 (3.9-12.1)		2.208 (1.138-4.286)	0.019	16 (8.3-23.7)		1.785 (0.917-3.475)	0.088	12 (3.0-21.0)		1.775 (0.957-3.289)	0.068
rs11168249			0.180				0.231				0.360
TT	33 (29.5)	8 (2.7-13.3)		1		20 (17.3-22.7)		1		20 (16.7-23.3)		1
TC	61 (54.5)	17 (11.3-22.7)		0.765 (0.462-1.268)	0.299	38 (22.6-53.4)		0.647 (0.385-1.087)	0.100	29 (16.3-41.7)		0.767 (0.469-1.254)	0.290
CC	18 (16.1)	7 (4.6-9.4)		1.353 (0.678-2.701)	0.391	31 (17.5-44.5)		0.880 (0.431-1.796)	0.726	24 (9.4-38.6)		1.121 (0.582-2.158)	0.733
rs1137101			0.014				0.262				0.452
AA	29 (25.9)	18 (0-48.5)		1		41 (21.5-60.5)		1		31 (7.6-54.4)		1
AG	54 (48.2)	13 (3.4-19.7)		1.445 (0.781-2.675)	0.241	30 (12.6-47.4)		1.102 (0.598-2.031)	0.755	28 (12.1-43.9)		0.919 (0.537-1.574)	0.760
GG	29 (25.9)	7 (6.2-7.8)		2.464 (1.268-4.790)	0.008	20 (12.2-27.8)		1.609 (0.832-3.111)	0.157	20 (13.0-27.0)		1.271 (0.706-2.290)	0.424
rs2736100			0.980				0.671				0.422
CC	31 (27.7)	11 (4.8-17.2)		1		22 (12.9-31.1)		1		20 (11.8-28.2)		1
CA	44 (39.3)	15 (8.9-21.1)		0.966 (0.559-1.670)	0.902	32 (20.3-43.7)		0.784 (0.442-1.391)	0.405	32 (20.3-43.7)		0.713 (0.414-1.230)	0.224
AA	29 (25.9)	11 (5.7-16.4)		1.022 (0.548-1.906)	0.946	29 (10.0-48.0)		0.792 (0.404-1.552)	0.497	20 (7.5-30.5)		0.924 (0.509-1.678)	0.795
rs3748816			0.282				0.639				0.688
AA	43 (38.4)	16 (8.4-23.6)		1		41 (17.9-64.1)		1		22 (1.0-43.0)		1
AG	50 (44.6)	8 (2.6-13.4)		1.432 (0.862-2.380)	0.166	25 (16.0-34.0)		1.224 (0.721-2.081)	0.454	25 (15.9-34.1)		0.978 (0.606-1.578)	0.926
GG	18 (16.1)	11 (4.8-17.2)		1.005 (0.514-1.965)	0.989	27 (20.1-33.9)		0.944 (0.469-1.900)	0.872	27 (20.1-33.9)		0.764 (0.399-1.462)	0.416
rs7528484			0.238				0.177				0.212
CC	32 (28.6)	18 (5.6-30.4)		1		30 (22.1-37.9)		1		28 (19.9-36.0)		1
CT	54 (48.2)	10 (5.1-14.9)		1.304 (0.775-2.194)	0.318	25 (19.2-30.9)		1.265 (0.740-2.163)	0.390	22 (13.9-30.1)		1.343 (0.806-2.239)	0.258
TT	26 (23.2)	15 (10.4-19.6)		0.807 (0.420-1.549)	0.519	86 (55.0-117.4)		0.693 (0.339-1.414)	0.313	32 (0-77.8)		0.831 (0.440-1.570)	0.569
Dominant model
rs10740055			0.152				0.536				0.549
CC	27 (24.1)	10 (5.1-14.9)		1		30 (6.5-53.5)		1		29 (11.9-46.1)		1
AA/CA	84 (75.0)	13 (7.1-18.9)		1.485 (0.851-2.590)	0.164	27 (17.5-36.5)		1.190 (0.681-2.081)	0.541	24 (17.5-30.5)		1.168 (0.699-1.952)	0.554
rs11168249			0.512				0.136				0.439
TT	33 (29.5)	8 (2.7-13.3)		1		20 (17.3-22.7)		1		20 (16.7-23.3)		1
CC/TC	79 (70.6)	13 (6.3-19.7)		0.855 (0.528-1.382)	0.522	31 (19.3-42.8)		0.692 (0.424-1.131)	0.142	28 (18.9-37.1)		0.833 (0.523-1.329)	0.444
rs1137101			0.059				0.424				0.902
AA	29 (25.9)	18 (0-48.5)		1		41 (21.5-60.5)		1		31 (7.6-54.4)		1
GG/AG	83 (74.1)	10 (6.5-13.5)		1.719 (0.960-3.079)	0.068	25 (18.0-32.0)		1.286 (0.917-1.803)	0.145	25 (17.9-32.1)		1.031 (0.627-1.698)	0.903
rs2736100			0.955				0.372				0.335
CC	31 (27.7)	11 (4.8-17.2)		1		22 (12.9-31.1)		1		20 (11.8-28.2)		1
AA/CA	73 (65.2)	12 (7.0-17.0)		0.986 (0.596-1.631)	0.956	32 (22.7-41.3)		0.787 (0.462-1.340)	0.377	29 (19.1-38.9)		0.786 (0.478-1.291)	0.341
rs3748816			0.287				0.613				0.682
AA	43 (38.4)	16 (8.4-23.6)		1		41 (17.9-64.1)		1		22 (1.0-43.0)		1
GG/AG	68 (60.7)	10 (5.8-14.2)		1.290 (0.798-2.086)	0.299	27 (22.0-32.0)		1.137 (0.688-1.877)	0.617	27 (22.4-37.6)		0.911 (0.581-1.428)	0.685
rs7528484			0.673				0.837				0.581
CC	32 (28.6)	18 (5.6-30.4)		1		30 (22.1-37.9)		1		28 (20.0-36.0)		1
TT/CT	80 (71.4)	11 (7.1-14.9)		1.109 (0.679-1.812)	0.680	27 (13.0-41.0)		1.055 (0.632-1.759)	0.838	24 (16.9-31.1)		1.144 (0.706-1.853)	0.585

¹Kaplan-Meier survival analysis.

²Univariate Cox regression analyses.

SNP: Single-nucleotide polymorphism; CI: Confidence interval; HR: Hazard ratio.

Full Size Table

Table 3 Multivariable Cox regression analysis of recurrence-free survival, cancer-specific survival and overall survival in intrahepatic cholangiocarcinoma

Variables	Recurrence-free survival		Cancer-specific survival		Overall survival
Variables	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Neoadjuvant therapy (no = 1)	5.346 (1.737-16.455)	0.003
LVI (no = 1)	3.749 (1.895-7.418)	< 0.001			5.524 (2.600-11.738)	< 0.001
Hemoglobin, g/L (≤ 12 = 1)			0.438 (0.222-0.867)	0.018	0.078 (0.013-0.486)	0.006
N category (pN0 = 1)			3.562 (1.802-7.041)	< 0.001
rs10740055 (CC/CA = 1)	2.413 (1.311-4.440)	0.005	2.265 (1.137-4.513)	0.020	4.095 (1.966-8.529)	< 0.001

Only significant parameters are shown. LVI: Lymph vascular invasion; CI: Confidence interval; HR: Hazard ratio.

Full Size Table

Table 4 Single nucleotide polymorphism frequencies and associations with recurrence-free survival, cancer-specific survival and overall survival in perihilar cholangiocarcinoma

SNP	n (%)	Recurrence-free survival				Cancer-specific survival				Overall survival
SNP	n (%)	Median (95%CI)	P value¹	HR (95%CI)	P value²	Median (95%CI)	P value¹	HR (95%CI)	P value²	Median (95%CI)	P value¹	HR (95%CI)	P value²
Recessive model
rs10740055			0.027				0.004				< 0.001
CC/CA	85 (72.6)	52 (22.1-81.9)		1		65 (31.8-98.2)		1		50 (38.7-61.3)		1
AA	32 (27.4)	15 (9.4-20.6)		1.840 (1.057-3.200)	0.031	19 (8.7-29.3)		2.184 (1.262-3.781)	0.005	14 (8.5-19.5)		1.840 (1.057-3.200)	0.001
rs1137101			0.460				0.843				0.647
AA/AG	92 (78.7)	31 (15.8-46.2)		1		45 (28.5-61.5)		1		32 (22.2-41.8)		1
GG	25 (21.4)	52 (25.0-79.0)		0.790 (0.420-1.486)	0.464	63 (19.4-106.6)		0.941 (0.516-1.718)	0.844	54 (13.8-94.2)		0.890 (0.537-1.473)	0.650
rs3184504			0.072				0.070				0.423
TT/TC	92 (78.6)	52 (18.6-85.4)		1		63 (36.0-90.0)		1		39 (22.5-55.5)		1
CC	32 (27.4)	19 (10.1-27.9)		1.618 (0.949-2.758)	0.077	29 (16.8-41.2)		1.102 (0.625-1.941)	0.737	19 (7.0-31.0)		1.214 (0.752-1.960)	0.428
rs3130			0.841				0.934				0.448
TT/TC	79 (67.6)	31 (13.0-49.0)		1		50 (28.2-71.8)		1		32 (21.1-42.9)		1
CC	26 (22.2)	52 (0-106.2)		1 (0.999-1.001)	0.586	33 (0-87.3)		1.000 (0.999-1.001)	0.804	30 (0-69.7)		1.000 (0.999-1.000)	0.257
rs3748816			0.616				0.211				0.668
AA/AG	105 (89.7)	39 (23.6-54.4)		1		51 (28.3-73.7)		1		38 (22.8-53.2)		1
GG	12 (10.3)	24 (12.8-35.3)		1.207 (0.574-2.535)	0.620	28 (20.4-35.6)		1.562 (0.769-3.174)	0.217	26 (20.9-31.1)		1.154 (0.596-2.232)	0.672
rs7528484			0.626				0.793				0.343
CC/CT	100 (85.5)	36 (24.0-48.0)		1		50 (23.9-76.1)		1		38 (25.0-51.0)		1
TT	17 (14.5)	55 (8.4-101.6)		0.824 (0.375-1.810)	0.629	84 (0-235.9)		0.949 (0.451-1.998)	0.891	27 (4.1-49.6)		1.306 (0.747-2.281)	0.349
Co-dominant model
rs10740055			0.060				0.015				0.002
CC	32 (27.4)	42 (29.5-54.5)		1		76 (39.9-112.1)		1		63 (45.3-80.8)		1
CA	53 (45.3)	67 (18.7-115.3)		0.759 (0.423-1.363)	0.356	63 (23.3-102.7)		0.913 (0.494-1.685)	0.770	41 (22.1-60.0)		1.218 (0.719-2.064)	0.462
AA	32 (27.4)	15 (9.4-20.6)		1.582 (0.842-2.971)	0.154	19 (8.7-29.3)		2.070 (1.077-3.977)	0.029	14 (8.5-19.5)		2.467 (1.392-4.373)	0.002
rs1137101			0.626				0.962				0.842
AA	34 (29.1)	24 (0-49.8)		1		51 (0-106.3)		1		29 (7.4-50.6)		1
AG	58 (49.6)	42 (2.9-81.1)		0.842 (0.482-1.472)	0.547	45 (28.5-61.5)		1.061 (0.584-1.927)	0.847	32 (23.1-40.9)		1.096 (0.664-1.808)	0.721
GG	25 (21.4)	52 (25.0-79.0)		0.712 (0.350-1.450)	0.349	63 (19.4-106.6)		0.976 (0.480-1.985)	0.947	54 (13.8-94.2)		0.942 (0.519-1.709)	0.843
rs3184504			0.130				0.180				0.723
TT	28 (23.9)	83 (58.2-107.5)		1		80.2 (56.6-103.8)		1		38 (22.3-53.7)		1
TC	57 (48.7)	45 (18.5-71.5)		1.404 (0.707-2.787)	0.332	63 (30.2-95.8)		1.154 (0.588-2.264)	0.677	49 (27.3-70.7)		0.977 (0.579-1.649)	0.931
CC	32 (27.4)	19 (10.1-27.9)		2.058 (0.984-4.302)	0.055	29 (16.8-41.2)		1.798 (0.878-3.683)	0.109	19 (7.0-31.0)		1.195 (0.661-2.163)	0.556
rs3130			0.652				0.926				0.863
TT	34 (29.1)	78 (25.7-130.3)		1		45 (0-106.1)		1		28 (10.9-45.1)		1
TC	45 (38.5)	25 (5.3-44.7)		0.875 (0.590-1.299)	0.508	50 (34.4-65.6)		0.908 (0.458-1.801)	0.782	38 (15.9-60.1)		0.987 (0.591-1.647)	0.960
CC	26 (22.2)	52 (0-106.2)		1.164 (0.818-1.657)	0.398	33 (0-87.3)		1.200 (0.629-2.290)	0.580	30 (0-69.7)		0.859 (0.473-1.562)	0.619
rs3748816			0.373				0.217				0.589
AA	50 (42.7)	37 (19.9-54.1)		1		50 (22.8-77.2)		1		33 (20.2-45.7)		1
AG	55 (47.0)	42 (0-96.1)		0.702 (0.413-1.192)	0.190	78 (61.9-94.2)		0.708 (0.410-1.222)	0.215	49 (29.2-68.8)		0.808 (0.517-1.264)	0.351
GG	12 (10.3)	24 (12.8-35.3)		1.005 (0.459-2.199)	0.990	28 (20.4-35.6)		1.312 (0.619-2.785)	0.479	26 (21.0-31.1)		1.033 (0.515-2.071)	0.927
rs7528484			0.855				0.758				0.471
CC	36 (30.8)	40 (13.1-66.9)		1		50 (9.3-90.7)		1		41 (22.4-59.6)		1
CT	64 (54.7)	31 (14.4-47.6)		1.077 (0.626-1.854)	0.788	45 (24.8-65.2)		1.231 (0.701-2.162)	0.469	31 (16.2-45.8)		1.214 (0.749-1.968)	0.431
TT	17 (14.5)	55 (8.4-101.6)		0.862 (0.366-2.031)	0.735	65 (10.4-119.6)		1.079 (0.472-2.465)	0.858	27 (4.1-49.9)		1.470 (0.778-2.777)	0.236
Dominant model
rs10740055			0.936				0.506				0.081
CC	32 (27.4)	42 (29.5-54.5)		1		76 (39.9-112.1)		1		63 (45.2-80.8)		1
AA/CA	85 (72.7)	29 (13.4-44.6)		0.979 (0.583-1.646)	0.937	39 (23.5-54.4)		1.205 (0.693-2.095)	0.509	30 (23.0-37.0)		1.531 (0.941-2.491)	0.087
rs1137101			0.400				0.912				0.865
AA	34 (29.0)	24 (0-49.8)		1		28 (0-106.3)		1		29 (7.4-50.6)		1
GG/AG	83 (71.0)	42 (17.0-67.0)		0.800 (0.474-1.352)	0.405	14 (21.2-76.8)		0.992 (0.700-1.404)	0.963	33 (19.5-46.5)		1.041 (0.650-1.667)	0.866
rs3184504			0.150				0.344				0.863
TT	28 (23.9)	82.8 (58.2-107.5)		1		80.2 (56.6-103.8)		1		38 (22.3-53.7)		1
CC/TC	89 (76.1)			1.599 (0.834-3.065)	0.158	49 (22.0-76.0)		1.353 (0.719-2.545)	0.349	32 (16.5-47.5)		1.044 (0.638-1.707)	0.864
rs3130			0.636				0.878				0.504
TT	34 (29.1)	78 (25.7-130.3)		1		45 (0-106.1)		1		28 (10.9-45.1)		1
CC/TC	71 (60.7)	29 (11.8-46.2)		1 (0.999-1.001)	0.587	50 (29.5-70.5)		1.000 (0.999-1.001)	0.804	38 (16.9-59.1)		1.000 (0.999-1.000)	0.258
rs3748816			0.262				0.408				0.436
AA	50 (42.7)	37 (19.9-54.1)		1		50 (22.8-77.2)		1		33 (20.3-45.7)		1
GG/AG	67 (57.3)	39 (0-83.3)		0.755 (0.460-1.240)	0.268	49 (12.4-85.6)		1.000 (0.999-1.001)	0.804	38 (20.3-55.7)		0.847 (0.555-1.293)	0.441
rs7528484			0.900				0.510				0.305
CC	36 (30.8)	40 (13.1-66.9)		1		50 (9.3-90.7)		1		41 (22.4-59.6)		1
TT/CT	81 (69.2)	36 (18.4-53.6)		1.034 (0.611-1.749)	0.901	49 (16.2-81.8)		1.199 (0.696-2.063)	0.513	31 (18.8-43.2)		1.269 (0.801-2.011)	0.310

¹Kaplan-Meier survival analysis.

²Univariate Cox regression analyses.

SNP: Single-nucleotide polymorphism; CI: Confidence interval; HR: Hazard ratio.

Full Size Table

Table 5 Multivariable Cox regression analysis of recurrence-free survival, cancer-specific survival and overall survival in perihilar cholangiocarcinoma

Variables	Recurrence-free survival		Cancer-specific survival		Overall survival
Variables	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Hemoglobin, g/L (≤ 12 = 1)	0.274 (0.146-0.516)	< 0.001	0.347 (0.180-0.668)	0.002	0.385 (0.226-0.654)	< 0.001
Intraoperative FFP (no = 1)	2.868 (1.501-5.480)	0.001	4.340 (2.094-8.994)	< 0.001	3.072 (1.762-3.354)	< 0.001
MVI (no = 1)	48.237 (8.791-264.662)	< 0.001	50.516 (8.685-293.835)	< 0.001	19.083 (3.880-93.844)	< 0.001
Tumor grading (G1/G2 = 1)	3.740 (1.711-8.177)	< 0.001	4.637 (2.109-10.193)	< 0.001	3.699 (1.879-7.284)	< 0.001
pT category (pT1-2 = 1)			2.573 (1.358-4.877)	0.004	2.227 (1.309-3.789)	0.003
N category (pN0 = 1)	2.704 (1.476-4.954)	0.001	2.524 (1.374-4.634)	0.003	1.779 (1.055-2.998)	0.031
Perioperative complications (Clavien-Dindo) (0/I/II = 1)					2.115 (1.279-3.497)	0.004

Only significant parameters are shown. FFP: Fresh frozen plasma; MVI: Microvascular invasion; CI: Confidence interval; HR: Hazard ratio.

Full Size Table

Citation: Wang G, Otto C, Liu D, Al-Masri TM, Lueong SS, Siveke J, Luedde T, Heise D, Vondran FW, Meister FA, Lurje G, Neumann U, Heij L, Bednarsch J. Prognostic significance of germline ARID5B and LEPR polymorphisms in intrahepatic and perihilar cholangiocarcinoma after curative resection. World J Gastrointest Oncol 2026; 18(7): 120469
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/120469.htm
DOI: https://dx.doi.org/10.4251/wjgo.120469

Wang G, Otto C, Liu D, Al-Masri TM, Lueong SS, Siveke J, Luedde T, Heise D, Vondran FW, Meister FA, Lurje G, Neumann U, Heij L, Bednarsch J. Prognostic significance of germline ARID5B and LEPR polymorphisms in intrahepatic and perihilar cholangiocarcinoma after curative resection. World J Gastrointest Oncol 2026; 18(7): 120469 [DOI: 10.4251/wjgo.120469]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.